Stable aqueous formulations of etanercept
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
1. A stabilized aqueous pharmaceutical composition having long term storage stability, comprising: etanercept and a stabilizer to inhibit instability, aggregation and/or fragmentation of the etanercept, wherein the composition is free of arginine as a stabilizer and wherein the stabilizer is 1 mM to 20 mM magnesium chloride.
2. The stabilized composition of claim 1 characterized by:
(a) an SEC (size exclusion chromatography) analysis at T 4 of greater than 90, 91, 92, 93, 94, 95, 96, or 97 wt. % monomer content; and less than 3, 2 or 1 wt. % aggregate(s) content; and
(b) an HIC (hydrophobic interaction chromatography) analysis at T 2 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than 3, 2 or 1 wt. %; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than 80, 81, 82, 83, 84 or 85 wt. %; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than 20, 19, 18, 17, 16, 15, 14, or 13 wt. %; and
(c) an HIC analysis at T 4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than 3, 2 or 1 wt. %; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than 80, 81, 82, 83, 84 or 85 wt. %; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than 20, 19, 18, 17, 16, 15, 14 or 13 wt. %.
3. The stabilized composition of claim 2 having an HIC analysis at T 4 or T 2 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than 2 wt. %; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than 85 wt. %; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than 13 wt. %.
4. The stabilized composition of claim 1 wherein the composition comprises 25 to 50 mg/ml of etanercept; optionally up to 6 wt. % sucrose; 25 to 150 mM NaCl; and 1 to 30 mM sodium phosphate and wherein the composition has a pH of 6.0 to pH 7.0.